Abstract
To evaluate treatment outcomes of intravitreal vascular endothelial growth factor (VEGF) in eyes with polypoidal choroidal vasculopathy (PCV) that exhibited poor baseline visual acuity. This retrospective, observational study included 47 eyes with treatment-naïve PCV with baseline visual acuity of 20/200 or worse treated with intravitreal anti-VEGF. Eyes were divided into 2 groups according to the presence of submacular hemorrhage (hemorrhage and no-hemorrhage groups). The best-corrected visual acuity (BCVA) at baseline was compared with that measured at 3 and 6 months after treatment. A mean of 3.3±0.9 intravitreal anti-VEGF injections were performed during the 6-month follow-up period. In the hemorrhage group (n=23), 6 patients additionally underwent pneumatic displacement with or without intravitreal tissue plasminogen activator. The logarithm of minimal angle of resolution BCVA at diagnosis, 3, and 6 months was 1.47±0.49, 0.91±0.79, and 0.81±0.83, respectively. Compared with baseline, BCVA was significantly better at 3 and 6 months (P=0.007 and P=0.001, respectively). In the no-hemorrhage group (n=24), the BCVA at defined time points was 1.23±0.32, 1.06±0.33, and 1.02±0.35, respectively. BCVA was significantly better at 3 a...Continue Reading
References
Jan 1, 1990·Retina·L A YannuzziB Lipson
Jan 1, 1995·Retina·R F SpaideD A Orlach
Jan 1, 1996·Retina·R L AveryN M Bressler
May 7, 2002·American Journal of Ophthalmology·Masanobu UyamaMiyo Matsumura
Jun 4, 2004·Japanese Journal of Ophthalmology·Masami NakajimaRyusaburo Mori
Nov 4, 2004·Ophthalmology·Neil M BresslerUNKNOWN Submacular Surgery Trials (SST) Research Group
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Jun 15, 2007·Retina·Taku SatoRyo Mukai
Jul 31, 2008·Retina·Rita EhrlichRuth Axer-Siegel
Feb 25, 2009·Indian Journal of Ophthalmology·Shobhit ChawlaMohit Khemchandani
Mar 24, 2009·The British Journal of Ophthalmology·S W KangJ-H Lee
Jun 13, 2009·The British Journal of Ophthalmology·T GalbinurI Chowers
Sep 19, 2009·Japanese Journal of Ophthalmology·Seungbum Kang, Young-Jung Roh
Feb 25, 2011·The New England Journal of Medicine·Deborah A Martin, Sanjaya Senanayake
Jun 21, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jost B JonasFrank C Schlichtenbrede
Dec 17, 2011·Journal of Ophthalmology·Leila El MatriHana Landoulsi
Jan 25, 2012·Acta Ophthalmologica·Helena Buch HesgaardMorten la Cour
Apr 3, 2012·American Journal of Ophthalmology·Kenji YamashiroNagahisa Yoshimura
Feb 23, 2013·The British Journal of Ophthalmology·Taiichi HikichiShoko Shioya
Mar 5, 2013·Retina·Adrian H C KohMitsuko Yuzawa
Mar 8, 2013·American Journal of Ophthalmology·Gary ShienbaumPhilip J Rosenfeld
Apr 25, 2013·Retina·Taiichi HikichiHideo Ohtsuka
May 15, 2013·Japanese Journal of Ophthalmology·Ryusaburo MoriMiho Haruyama
Jul 16, 2013·Retina·Pierluigi IaconoFrancesco Bandello
Jul 24, 2013·American Journal of Ophthalmology·Akio OishiAkira Negi
Aug 21, 2013·Seminars in Ophthalmology·Sameera NayakTaraprasad Das
Aug 21, 2013·American Journal of Ophthalmology·Jae Hui KimJeeyun Ahn
Sep 24, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Abdullah OzkayaAhmet Demirok
Dec 18, 2013·Ophthalmology·Jae Hui KimHan Ju Cho
Oct 25, 2014·PloS One·Wei WangXiulan Zhang